- Home
- MYGN vs KBDC Comparison
MYGN vs KBDC Comparison
Compare MYGN & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- KBDC
- Stock Information
- Founded
- MYGN 1991
- KBDC 2021
- Country
- MYGN United States
- KBDC United States
- Employees
- MYGN N/A
- KBDC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- KBDC
- Sector
- MYGN Health Care
- KBDC
- Exchange
- MYGN Nasdaq
- KBDC Nasdaq
- Market Cap
- MYGN 1.2B
- KBDC 1.2B
- IPO Year
- MYGN 1995
- KBDC N/A
- Fundamental
- Price
- MYGN $14.18
- KBDC $17.40
- Analyst Decision
- MYGN Hold
- KBDC Buy
- Analyst Count
- MYGN 13
- KBDC 5
- Target Price
- MYGN $22.54
- KBDC $17.30
- AVG Volume (30 Days)
- MYGN 1.2M
- KBDC 102.4K
- Earning Date
- MYGN 02-24-2025
- KBDC 03-03-2025
- Dividend Yield
- MYGN N/A
- KBDC 2.29%
- EPS Growth
- MYGN N/A
- KBDC N/A
- EPS
- MYGN N/A
- KBDC N/A
- Revenue
- MYGN $823,600,000.00
- KBDC N/A
- Revenue This Year
- MYGN $13.60
- KBDC $193.84
- Revenue Next Year
- MYGN $3.25
- KBDC $15.95
- P/E Ratio
- MYGN N/A
- KBDC N/A
- Revenue Growth
- MYGN 12.15
- KBDC N/A
- 52 Week Low
- MYGN $12.04
- KBDC $15.69
- 52 Week High
- MYGN $29.30
- KBDC $17.99
- Technical
- Relative Strength Index (RSI)
- MYGN 55.82
- KBDC N/A
- Support Level
- MYGN $14.13
- KBDC N/A
- Resistance Level
- MYGN $15.47
- KBDC N/A
- Average True Range (ATR)
- MYGN 0.72
- KBDC 0.00
- MACD
- MYGN 0.27
- KBDC 0.00
- Stochastic Oscillator
- MYGN 61.38
- KBDC 0.00
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.